Higher Crohn's disease rates with vedolizumab: a study

Published Date: 13 Mar 2023

The study results may prompt doctors to choose vedolizumab over anti-TNF therapy as the first-line treatment for Crohn's disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Panel Supports More Clarity in NSCLC Perioperative Immunotherapy Trials

2.

ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death

3.

Are patients with advanced cancer receiving treatment aligned with their goals?

4.

PFS in Multiple Myeloma Is Improved by Daratumumab Added to Standard Therapy.

5.

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot